In a recent study of ovarian cancer ascites using multiplex bead-based immunoassays, high concentrations of 2 common inflammatory factors, matrix metalloproteinase 2 and 3, were identified as predictors of shorter platinum-free intervals in patients treated with neoadjuvant chemotherapy or primary debulking surgery [51]. This evidence concerns the gene MMP2 and ovarian cancer.